Monte Rosa Therapeutics (GLUE) Short Interest Ratio & Short Volume → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free GLUE Stock Alerts $3.98 -0.21 (-5.01%) (As of 06/7/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Monte Rosa Therapeutics Short Interest DataCurrent Short Interest2,310,000 sharesPrevious Short Interest1,910,000 sharesChange Vs. Previous Month+20.94%Dollar Volume Sold Short$12.08 millionShort Interest Ratio13.8 Days to CoverLast Record DateMay 15, 2024Outstanding Shares50,510,000 sharesFloat Size38,610,000 sharesShort Percent of Float5.98%Today's Trading Volume215,714 sharesAverage Trading Volume264,737 sharesToday's Volume Vs. Average81% Short Selling Monte Rosa Therapeutics ? Sign up to receive the latest short interest report for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGLUE Short Interest Over TimeGLUE Days to Cover Over TimeGLUE Percentage of Float Shorted Over Time Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", Monte Rosa Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20242,310,000 shares $12.08 million +20.9%6.0%13.8 $5.23 4/30/20241,910,000 shares $10.16 million +2.1%6.0%13.7 $5.32 4/15/20241,870,000 shares $12.29 million +11.3%5.9%14.2 $6.57 3/31/20241,680,000 shares $11.84 million -8.2%5.3%11.2 $7.05 3/15/20241,830,000 shares $11.73 million -0.5%5.8%11.2 $6.41 2/29/20241,840,000 shares $11.65 million -7.1%5.8%9.6 $6.33 Get the Latest News and Ratings for GLUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/20241,980,000 shares $10.95 million +3.7%6.3%9.6 $5.53 1/31/20241,910,000 shares $10.12 million -2.6%6.1%9.1 $5.30 1/15/20241,960,000 shares $11.76 million -4.9%6.2%8 $6.00 12/31/20232,060,000 shares $11.64 million -12.7%6.5%6.6 $5.65 12/15/20232,360,000 shares $11.80 million -20.5%7.5%7.7 $5.00 11/30/20232,970,000 shares $9.21 million -2.9%9.4%10.7 $3.10 11/15/20233,060,000 shares $11.26 million -8.7%9.7%12.1 $3.68 10/31/20233,350,000 shares $11.39 million -10.2%10.8%12.4 $3.40 10/15/20233,730,000 shares $18.02 million -6.8%12.1%15.6 $4.83 9/30/20234,000,000 shares $19.16 million +4.4%12.9%25.8 $4.79 9/15/20233,830,000 shares $23.02 million +7.9%12.4%25.8 $6.01 8/31/20233,550,000 shares $20.84 million +14.2%11.5%23.3 $5.87 8/15/20233,110,000 shares $20.46 million +11.1%10.0%19 $6.58 7/31/20232,800,000 shares $19.80 million +6.5%7.0%19.3 $7.07 7/15/20232,630,000 shares $18.33 million +1.9%6.6%14.1 $6.97 6/30/20232,580,000 shares $17.67 million +5.7%6.5%12.3 $6.85 6/15/20232,440,000 shares $18.03 million +6.6%6.1%11.9 $7.39 5/31/20232,290,000 shares $16.90 million No Change5.8%12 $7.38 5/15/20232,290,000 shares $13.40 million +2.2%5.8%13.5 $5.85 4/30/20232,240,000 shares $10.17 million -10.0%5.6%13.5 $4.54 4/15/20232,490,000 shares $17.06 million +2.9%6.3%16.5 $6.85 3/31/20232,420,000 shares $18.85 million +9.0%6.1%17.2 $7.79 3/15/20232,220,000 shares $14.50 million -3.1%5.6%15.9 $6.53 2/28/20232,290,000 shares $13.92 million -8.0%5.9%15.8 $6.08 2/15/20232,490,000 shares $16.98 million -33.2%6.4%17.1 $6.82 1/31/20233,730,000 shares $27.60 million -0.8%9.6%22.6 $7.40 1/15/20233,760,000 shares $29.37 million -13.4%9.7%25.9 $7.81 12/30/20224,340,000 shares $33.03 million +1.4%11.2%27.7 $7.61 12/15/20224,280,000 shares $40.57 million -1.8%11.1%24 $9.48 11/30/20224,360,000 shares $36.97 million -6.6%14.6%20.1 $8.48 11/15/20224,670,000 shares $43.99 million -4.3%15.7%20.7 $9.42 10/31/20224,880,000 shares $44.90 million +1.2%16.4%21.3 $9.20 10/15/20224,820,000 shares $37.45 million -6.2%16.2%21.3 $7.77 9/30/20225,140,000 shares $41.99 million +4.5%17.3%23 $8.17No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (Ad)Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY 9/15/20224,920,000 shares $39.26 million -3.3%16.6%24.2 $7.98 8/31/20225,090,000 shares $40.31 million +6.5%17.2%26.3 $7.92 8/15/20224,780,000 shares $47.51 million +3.5%16.1%23.4 $9.94 7/31/20224,620,000 shares $41.90 million No Change15.6%23.8 $9.07 7/15/20224,620,000 shares $47.36 million -0.9%15.6%23.8 $10.25 6/30/20224,660,000 shares $45.06 million -5.5%15.7%23.2 $9.67 6/15/20224,930,000 shares $37.76 million -13.7%16.6%23.6 $7.66 5/31/20225,710,000 shares $44.20 million +1.1%19.3%22.2 $7.74 5/15/20225,650,000 shares $46.27 million -0.2%19.1%21 $8.19 4/30/20225,660,000 shares $61.69 million -1.9%19.1%20.4 $10.90 4/15/20225,770,000 shares $78.88 million -3.4%19.5%18.9 $13.67 3/31/20225,970,000 shares $83.70 million +10.8%N/A18.9 $14.02 3/15/20225,390,000 shares $75.24 million +8.0%18.3%17.1 $13.96 2/28/20224,990,000 shares $71.56 million +10.9%16.9%21.1 $14.34 2/15/20224,500,000 shares $65.16 million +32.0%15.3%20.1 $14.48 1/31/20223,410,000 shares $43.17 million -3.1%11.6%17 $12.66 1/15/20223,520,000 shares $52.80 million +5.4%N/A21 $15.00 12/31/20213,340,000 shares $68.20 million +3.4%11.3%22.7 $20.42 12/15/20213,230,000 shares $59.79 million +17.0%11.0%23.4 $18.51 11/30/20212,760,000 shares $53.52 million +9.1%9.4%15.8 $19.39 11/15/20212,530,000 shares $58.19 million -0.4%8.6%13.7 $23.00 10/29/20212,540,000 shares $59.56 million +5.8%9.3%12.8 $23.45 10/15/20212,400,000 shares $50.88 million -5.1%8.8%11.5 $21.20 9/30/20212,530,000 shares $56.37 million +30.4%9.3%11.2 $22.28 9/15/20211,940,000 shares $62.82 million +12.8%7.1%6.1 $32.38 8/31/20211,720,000 shares $61.39 million +44.5%6.5%5.8 $35.69 8/13/20211,190,000 shares $40.25 million No Change5.9%3.8 $33.82 GLUE Short Interest - Frequently Asked Questions What is Monte Rosa Therapeutics' current short interest? Short interest is the volume of Monte Rosa Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 2,310,000 shares of GLUE short. 5.98% of Monte Rosa Therapeutics' shares are currently sold short. Learn More on Monte Rosa Therapeutics' current short interest. What is a good short interest ratio for Monte Rosa Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GLUE shares currently have a short interest ratio of 14.0. Learn More on Monte Rosa Therapeutics's short interest ratio. What is a good short interest percentage for Monte Rosa Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.98% of Monte Rosa Therapeutics' floating shares are currently sold short. Is Monte Rosa Therapeutics' short interest increasing or decreasing? Monte Rosa Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,310,000 shares, an increase of 20.9% from the previous total of 1,910,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Monte Rosa Therapeutics' float size? Monte Rosa Therapeutics currently has issued a total of 50,510,000 shares. Some of Monte Rosa Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Monte Rosa Therapeutics currently has a public float of 38,610,000 shares. How does Monte Rosa Therapeutics' short interest compare to its competitors? 5.98% of Monte Rosa Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Monte Rosa Therapeutics: Invivyd, Inc. (9.17%), Seres Therapeutics, Inc. (15.01%), Kinnate Biopharma Inc. (2.01%), bluebird bio, Inc. (28.90%), Kronos Bio, Inc. (1.67%), Icosavax, Inc. (0.99%), Nurix Therapeutics, Inc. (14.81%), ProKidney Corp. (21.99%), Scholar Rock Holding Co. (16.71%), CARGO Therapeutics, Inc. (13.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Monte Rosa Therapeutics stock? Short selling GLUE is an investing strategy that aims to generate trading profit from Monte Rosa Therapeutics as its price is falling. GLUE shares are trading down $0.21 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Monte Rosa Therapeutics? A short squeeze for Monte Rosa Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GLUE, which in turn drives the price of the stock up even further. How often is Monte Rosa Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GLUE, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: IVVD Short Squeeze MCRB Short Squeeze KNTE Short Squeeze BLUE Short Squeeze KRON Short Squeeze ICVX Short Squeeze NRIX Short Squeeze PROK Short Squeeze SRRK Short Squeeze CRGX Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GLUE) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.